LabMedica

Download Mobile App
Recent News Expo Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

Binding Site Unveils Optilite Protein System

By LabMedica International staff writers
Posted on 09 Feb 2017
Image: The Optilite protein system (Photo courtesy of The Binding Site).
Image: The Optilite protein system (Photo courtesy of The Binding Site).
The Binding Site, which provides specialist diagnostic products to clinicians and laboratory professionals worldwide, launched its new optimized protein system, Optilite in the Middle East, at MEDLAB 2017, the world’s largest laboratory exhibition and congress in the region.

Binding Site focuses on research, development, manufacture and distribution of immunodiagnostic systems and assays for the global laboratory market. By utilizing its specialized expertise in antibody specificity technology, it has developed a broad menu of special protein assays. Binding Site gives clinicians and laboratory staff the tools to significantly improve diagnosis and management of patients with specific cancers and immune disorders.

The company has designed Optilite, a dedicated benchtop special protein analyzer, specifically for laboratory workflow optimization. Optilite’s continuous loading of samples, reagents, and consumables plus automatic re-dilution to end result enable labs to maximize test throughput while minimizing hands-on time. With a compact benchtop design, Optilite is quick to install, easy to maintain, and is equipped with full LIS connectivity and automatic barcode recognition for full traceability. Unique to Optilite is a robust antigen excess protection system with three detection methods, thereby ensuring accurate and reliable results.

New
Gold Member
Automatic Hematology Analyzer
CF9600
POC Helicobacter Pylori Test Kit
Hepy Urease Test
New
Clinical Informatics Platform
CLARION™
New
Pipette Calibration System
Artel PCS®

Channels

Immunology

view channel
Image: Accurate immunotherapy selection for esophageal and GEJ carcinomas depends on consistent PD-L1 assessment (credit: Adobe Stock)

FDA Approval Expands Use of PD-L1 Companion Diagnostic in Esophageal and GEJ Carcinomas

Esophageal and gastroesophageal junction carcinomas (GEJ) have a poor prognosis, with approximately 16,250 deaths in the United States in 2025 and a five-year relative survival of 21.9%.... Read more
INTEGRA BIOSCIENCES AG